By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
A SuperPowered CRO Joining Forces with Superpowered Clients
Together, we’re ready to save the world, one medical device or drug at a time. Come join us as the superhero saga continues…
We know your needs. We know the pitfalls of the submission process and how to avoid them. We’re here to make it happen— from concept to market.
You have an innovative medical device or drug, and you need an organization experienced in getting products approved and on the market.
Inc. 5000 Award
Proxima Clinical Research Ranks in the Top 25% of the Fastest Growing Private Companies in the USA
Proxima placed 1116 out of 5000 fast-growing companies in the U.S., and placed 105 among Texas based companies, 58 among health services companies, and 14 among Houston-based companies. According to Inc., this honor places Proxima CRO among top 0.07 percent of businesses in the nation.
FDA Issues Breakthrough Device Certification for Proxima Client Sigi™
Sigi™ provides a modern solution in the treatment of diabetes mellitus. It is the only insulin patch pump for closed loop integration designed for use with standard, pre-filled pump cartridges. Sigi™ can be programmed to deliver basal and bolus insulin at both set and variable rates via a Bluetooth-compatible continuous glucose monitors or alternative controller devices such as a smartphone or an iController.
From regulatory consulting to clinical research, Proxima is a full-service Contract Research Organization
Proxima works with emerging biotech and medical device companies across all phases of development. As a contract research organization, we organize our team in two distinct areas: early stage advisory consulting and all-inclusive clinical trial services. The service you need. The speed you want. The attention you deserve.
Proxima has been an important piece of Memgen's regulatory and clinical achievements for multiple years now, playing a vital role in our IND approval, clinical launch, and trial management of our first-in-human study of our lead cancer immunotherapy biologic. Proxima and its growing team have continually shown their experience, broad skill sets, adaptability to our company's needs and objectives, and value in an industry with a myriad of CROs to choose from.
Mark Cantwell
CSO
"Proxima staff understood the needs of our company and took a vested interest in supporting our clinical trial’s aggressive timeline while safeguarding our goals and objectives. Proxima has been a true partner for our early stage medical device startup!"
Zaffer Syed
Sr. VP, Marketing & Clinical Development
"The wonderful people at Proxima have been dogged champions for our success. Aside from being deeply experienced in our particular field and keenly knowledgeable on developing trends they take our success as personally as we do. That, as much as anything, has been the difference."
